Differences between angiotensin-converting enzyme inhibition and angiotensin II-AT1 antagonism on angiotensin-mediated responses in human internal mammary arteries

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 2, 2003, Pages 178-184

  Voors, Adriaan A ^a   Oosterga, Margreeth ^b   Buikema, Hendrik ^b   Mariani, Massimo ^b   Grandjean, Jan G ^b   Van Gilst, Wiek H ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b NONE

Author keywords

Angiotensin; Contractile function; Renin angiotensin system; Vasoactive agents; Vasoconstriction dilatation

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; PHENYLEPHRINE; SOYBEAN TRYPSIN INHIBITOR;

ARTERY CONSTRICTION; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; INTERNAL MAMMARY ARTERY; PRIORITY JOURNAL; VASOCONSTRICTION; VASODILATATION;

AGED; AGED, 80 AND OVER; ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAMMARY ARTERIES; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN;

EID: 0037309171     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200302000-00005     Document Type: Article

References (21)

1. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-6.
2. Aldigier JC, Huang H, Dalmay F, et al. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol. 1993;21:289-95.
3. Miura S, Ideishi M, Sakai T, et al. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens. 1994;12:1177-81.
4. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21:53-7.
5. Rousseau MF, Konstam MA, Benedict CR, et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol. 1994;73:488-93.
6. Massie BM. Neurohormonal blockade in chronic heart failure: How much is enough? Can there be too much? J Am Coll Cardiol. 2002;39:79-82.
7. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-90.
8. Voors AA, Pinto YM, Buikema H, et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol. 1998;125:1028-32.
9. Michel B, Grima M, Stephan D, et al. Plasma renin activity and changes in tissue angiotensin converting enzyme. J Hypertens. 1994;12:577-84.
10. Buikema H, Grandjean JG, van den Broek S, et al. Differences in vasomotor control between human gastroepiploic and left internal mammary artery. Circulation. 1992;86 (suppl):II-205-9.
11. Buikema H, Pinto YM, Rooks G, et al. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J. 1996;17:787-94.
12. Yang ZH, von Segesser L, Bauer E, et al. Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res. 1991;68:52-60.
13. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res. 1994;28:303-11.
14. Borland JA, Chester AH, Morrison KA, et al. Alternative pathways of angiotensin II production in the human saphenous vein. Br J Pharmacol. 1998;125:423-8.
15. Oosterga M, Voors AA, Buikema H, et al. Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators. Cardiovasc Drugs Ther. 2000;14:55-60.
16. Padmanabhan N, Jardine AG, McGrath JC, et al. Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries. Circulation. 1999;99:2914-20.
17. van Veldhuisen DJ, Voors AA. Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers. Eur Heart J. 2000;21:14-6.
18. Wilson Tang WH, Vagelos RH, Yee YG, et al. Neurohormonal and clinical responses to. J Am Coll Cardiol. 2002;39:70-8.
19. Mangiapane ML, Rauch AL, MacAndrew JT, et al. Vasoconstrictor action of angiotensin I-convertase and the synthetic substrate (Pro 11,D-Ala12)-angiotensin I. Hypertension. 1994;23(6 part 2):857-60.
20. Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
21. Carey RM, Jin XH, Siragy HM. Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens. 2001;14(6 part 2):98S-102S.